Specificity mapping of HIV-1 protease by reduced bond inhibitors

P. Majer, J. Urban, E. Gregorova, J. Konvalinka, P. Novek, J. Stehlikova, Martin Andreansky, J. Sedlacek, P. Strop

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

A series of 47 N-truncated reduced bond inhibitors, systematically modified at individual positions (P1, P'1, P'2, P'3, and P'4), were synthesized and used to map the subsite preferences of HIV-1 protease. The tight binding inhibitor of HIV-1 protease t-butoxycarbonyl-Phe[CH2NH]Phe-Glu-Phe-NH2 (K(i) = 0.2 nM) was chosen as the parent structure for further modifications. The P'2 glutamic acid was found to fit well into the S'2 subsite of the protease. The conformational restriction of any phenylalanine residue or saturation of more than one phenylalanine side chain in P'1 or P'3 lead is to a large K(i) increase. Introduction of tyrosine in the P1 position improves the binding by an order of magnitude. The S'4 subsite of the protease was shown to accommodate large structural changes in the inhibitor at this position. Therefore P'4 may serve as an ideal region for further modification in order to improve bioavailability of this type of compound. An improved method of direct comparison of tight binding inhibitors with subnanomolar K(i) values has been described.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalArchives of Biochemistry and Biophysics
Volume304
Issue number1
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Phenylalanine
Peptide Hydrolases
Biological Availability
Tyrosine
Glutamic Acid
Human immunodeficiency virus 1 p16 protease
Lead

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Majer, P., Urban, J., Gregorova, E., Konvalinka, J., Novek, P., Stehlikova, J., ... Strop, P. (1993). Specificity mapping of HIV-1 protease by reduced bond inhibitors. Archives of Biochemistry and Biophysics, 304(1), 1-8. https://doi.org/10.1006/abbi.1993.1314

Specificity mapping of HIV-1 protease by reduced bond inhibitors. / Majer, P.; Urban, J.; Gregorova, E.; Konvalinka, J.; Novek, P.; Stehlikova, J.; Andreansky, Martin; Sedlacek, J.; Strop, P.

In: Archives of Biochemistry and Biophysics, Vol. 304, No. 1, 01.01.1993, p. 1-8.

Research output: Contribution to journalArticle

Majer, P, Urban, J, Gregorova, E, Konvalinka, J, Novek, P, Stehlikova, J, Andreansky, M, Sedlacek, J & Strop, P 1993, 'Specificity mapping of HIV-1 protease by reduced bond inhibitors', Archives of Biochemistry and Biophysics, vol. 304, no. 1, pp. 1-8. https://doi.org/10.1006/abbi.1993.1314
Majer P, Urban J, Gregorova E, Konvalinka J, Novek P, Stehlikova J et al. Specificity mapping of HIV-1 protease by reduced bond inhibitors. Archives of Biochemistry and Biophysics. 1993 Jan 1;304(1):1-8. https://doi.org/10.1006/abbi.1993.1314
Majer, P. ; Urban, J. ; Gregorova, E. ; Konvalinka, J. ; Novek, P. ; Stehlikova, J. ; Andreansky, Martin ; Sedlacek, J. ; Strop, P. / Specificity mapping of HIV-1 protease by reduced bond inhibitors. In: Archives of Biochemistry and Biophysics. 1993 ; Vol. 304, No. 1. pp. 1-8.
@article{b70bba91ca5d420bbc72f0249fd6026a,
title = "Specificity mapping of HIV-1 protease by reduced bond inhibitors",
abstract = "A series of 47 N-truncated reduced bond inhibitors, systematically modified at individual positions (P1, P'1, P'2, P'3, and P'4), were synthesized and used to map the subsite preferences of HIV-1 protease. The tight binding inhibitor of HIV-1 protease t-butoxycarbonyl-Phe[CH2NH]Phe-Glu-Phe-NH2 (K(i) = 0.2 nM) was chosen as the parent structure for further modifications. The P'2 glutamic acid was found to fit well into the S'2 subsite of the protease. The conformational restriction of any phenylalanine residue or saturation of more than one phenylalanine side chain in P'1 or P'3 lead is to a large K(i) increase. Introduction of tyrosine in the P1 position improves the binding by an order of magnitude. The S'4 subsite of the protease was shown to accommodate large structural changes in the inhibitor at this position. Therefore P'4 may serve as an ideal region for further modification in order to improve bioavailability of this type of compound. An improved method of direct comparison of tight binding inhibitors with subnanomolar K(i) values has been described.",
author = "P. Majer and J. Urban and E. Gregorova and J. Konvalinka and P. Novek and J. Stehlikova and Martin Andreansky and J. Sedlacek and P. Strop",
year = "1993",
month = "1",
day = "1",
doi = "10.1006/abbi.1993.1314",
language = "English",
volume = "304",
pages = "1--8",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Specificity mapping of HIV-1 protease by reduced bond inhibitors

AU - Majer, P.

AU - Urban, J.

AU - Gregorova, E.

AU - Konvalinka, J.

AU - Novek, P.

AU - Stehlikova, J.

AU - Andreansky, Martin

AU - Sedlacek, J.

AU - Strop, P.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - A series of 47 N-truncated reduced bond inhibitors, systematically modified at individual positions (P1, P'1, P'2, P'3, and P'4), were synthesized and used to map the subsite preferences of HIV-1 protease. The tight binding inhibitor of HIV-1 protease t-butoxycarbonyl-Phe[CH2NH]Phe-Glu-Phe-NH2 (K(i) = 0.2 nM) was chosen as the parent structure for further modifications. The P'2 glutamic acid was found to fit well into the S'2 subsite of the protease. The conformational restriction of any phenylalanine residue or saturation of more than one phenylalanine side chain in P'1 or P'3 lead is to a large K(i) increase. Introduction of tyrosine in the P1 position improves the binding by an order of magnitude. The S'4 subsite of the protease was shown to accommodate large structural changes in the inhibitor at this position. Therefore P'4 may serve as an ideal region for further modification in order to improve bioavailability of this type of compound. An improved method of direct comparison of tight binding inhibitors with subnanomolar K(i) values has been described.

AB - A series of 47 N-truncated reduced bond inhibitors, systematically modified at individual positions (P1, P'1, P'2, P'3, and P'4), were synthesized and used to map the subsite preferences of HIV-1 protease. The tight binding inhibitor of HIV-1 protease t-butoxycarbonyl-Phe[CH2NH]Phe-Glu-Phe-NH2 (K(i) = 0.2 nM) was chosen as the parent structure for further modifications. The P'2 glutamic acid was found to fit well into the S'2 subsite of the protease. The conformational restriction of any phenylalanine residue or saturation of more than one phenylalanine side chain in P'1 or P'3 lead is to a large K(i) increase. Introduction of tyrosine in the P1 position improves the binding by an order of magnitude. The S'4 subsite of the protease was shown to accommodate large structural changes in the inhibitor at this position. Therefore P'4 may serve as an ideal region for further modification in order to improve bioavailability of this type of compound. An improved method of direct comparison of tight binding inhibitors with subnanomolar K(i) values has been described.

UR - http://www.scopus.com/inward/record.url?scp=0027293060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027293060&partnerID=8YFLogxK

U2 - 10.1006/abbi.1993.1314

DO - 10.1006/abbi.1993.1314

M3 - Article

C2 - 8323274

AN - SCOPUS:0027293060

VL - 304

SP - 1

EP - 8

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

IS - 1

ER -